Interesting Image

Oncological Follow-up with 2-[¹⁸F]-FDG PET/CT in Li-Fraumeni Syndrome

10.4274/mirt.galenos.2020.33255

• Marylin Acuña Hernandez
• Iván Fabricio Vega Gonzalez
• Lina López Vélez
• Catalina Melo Arango

Received Date: 10.11.2019 Accepted Date: 24.04.2020 Mol Imaging Radionucl Ther 2021;30(2):110-112 PMID: 34082513

• Abstract
• Full Text
• Video - Image
• References
• 1
• 1075

Li-Fraumeni syndrome is a rare disorder caused by abnormalities of the tumor-suppressor protein P53 gene. We present the case of a 26-years-old female diagnosed with bilateral ductal carcinoma. The genetic panel for breast cancer gene 1 (BRCA1) and BRCA2 mutations was negative and positive heterozygous germline tumor protein P53 gene mutations, considering Li-Fraumeni syndrome. A 2-[¹⁸F]-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) was used for postsurgical staging to show the right lung hypermetabolic nodule. A lobectomy was accomplished, and histopathology reported pulmonary adenocarcinoma. A year later, oncological follow-up was conducted with 2-[¹⁸F]-FDG PET/CT without evidence of abnormalities.

Keywords: Li-Fraumeni syndrome, positron emission tomography, fluorodeoxyglucose 18F

Ethics

Informed Consent: Informed consent was obtained from patient.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: M.A.H., I.F.V.G., L.L.V., C.M.A., Concept: M.A.H., I.F.V.G., Design: M.A.H., I.F.V.G., Data Collection or Processing: M.A.H., I.F.V.G., L.L.V., C.M.A., Analysis or Interpretation: M.A.H., I.F.V.G., L.L.V., C.M.A., Literature Search: M.A.H., Writing: M.A.H., I.F.V.G., L.L.V., C.M.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

Images

1. Aedma SK, Kasi A. Li-Fraumeni Syndrome. 2020 Nov 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
2. McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM, Mitchell G. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 2014;11:260-271.
3. Nogueira ST, Lima EN, Nóbrega AF, Torres Ido C, Cavicchioli M, Hainaut P, Achatz MI. (18)F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome. Front Oncol 2015;19;5:38.